Literature DB >> 34162658

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.

Michael C J Quinn1, Karen McCue1, Stuart MacGregor1, Georgia Chenevix-Trench2, Wei Shi1, Sharon E Johnatty1, Jonathan Beesley1, Andrew Civitarese1, Tracy A O'Mara1, Dylan M Glubb1, Jonathan P Tyrer3, Sebastian M Armasu4, Jue-Sheng Ong1, Puya Gharahkhani1, Yi Lu1, Bo Gao5,6, Ann-Marie Patch1, Peter A Fasching7,8, Matthias W Beckmann8, Diether Lambrechts9,10, Ignace Vergote11, Digna R Velez Edwards12, Alicia Beeghly-Fadiel13, Javier Benitez14, Maria J Garcia14,15, Marc T Goodman16,17, Thilo Dörk18, Matthias Dürst19, Francesmary Modugno20,21,22, Kirsten Moysich23, Andreas du Bois24,25, Jacobus Pfisterer26, Klaus Bauman, Beth Y Karlan27, Jenny Lester27, Julie M Cunningham28, Melissa C Larson4, Bryan M McCauley4, Susanne K Kjaer29,30, Allan Jensen31, Claus K Hogdall29, Estrid Hogdall30,31, Joellen M Schildkraut32, Marjorie J Riggan33, Andrew Berchuck33, Daniel W Cramer34, Kathryn L Terry34,35, Line Bjorge36,37, Penelope M Webb, Michael Friedlander38, Tanja Pejovic39,40, Melissa Moffitt39,40, Rosalind Glasspool41, Taymaa May42, Gabrielle E V Ene42, David G Huntsman43,44,45,46, Michelle Woo47, Michael E Carney48, Samantha Hinsley49, Florian Heitz24,25,50, Sian Fereday51, Catherine J Kennedy6,52, Stacey L Edwards1, Stacey J Winham4, Anna deFazio, Paul D P Pharoah3,53, Ellen L Goode4.   

Abstract

BACKGROUND: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance.
METHODS: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy.
RESULTS: We found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10-8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15-1.34; P = 1.47 × 10-8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro.
CONCLUSIONS: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. IMPACT: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options.See related commentary by Peres and Monteiro, p. 1604. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34162658      PMCID: PMC8419101          DOI: 10.1158/1055-9965.EPI-20-1817

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  56 in total

1.  The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis.

Authors:  R A Veldhoen; S L Banman; D R Hemmerling; R Odsen; T Simmen; A J Simmonds; D A Underhill; I S Goping
Journal:  Oncogene       Date:  2012-03-19       Impact factor: 9.867

2.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.

Authors:  Balázs Gyorffy; András Lánczky; Zoltán Szállási
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

Review 3.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

4.  The support of human genetic evidence for approved drug indications.

Authors:  Matthew R Nelson; Hannah Tipney; Jeffery L Painter; Judong Shen; Paola Nicoletti; Yufeng Shen; Aris Floratos; Pak Chung Sham; Mulin Jun Li; Junwen Wang; Lon R Cardon; John C Whittaker; Philippe Sanseau
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

5.  UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.

Authors:  Masatomo Nishikawa; Hideaki Miyake; Liu Bing; Masato Fujisawa
Journal:  Urol Oncol       Date:  2015-08-20       Impact factor: 3.498

6.  hichipper: a preprocessing pipeline for calling DNA loops from HiChIP data.

Authors:  Caleb A Lareau; Martin J Aryee
Journal:  Nat Methods       Date:  2018-02-28       Impact factor: 28.547

Review 7.  PI3K/AKT/mTOR inhibitors in ovarian cancer.

Authors:  M Mazzoletti; M Broggini
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

8.  Evolution of platinum resistance in high-grade serous ovarian cancer.

Authors:  Susanna L Cooke; James D Brenton
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

9.  Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.

Authors:  Yuan Xu; Lei Cheng; Hongji Dai; Ruoxin Zhang; Mengyun Wang; Tingyan Shi; Menghong Sun; Xi Cheng; Qingyi Wei
Journal:  J Cell Mol Med       Date:  2018-07-28       Impact factor: 5.310

10.  Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

Authors:  Sharon E Johnatty; Jonathan P Tyrer; Siddhartha Kar; Jonathan Beesley; Yi Lu; Bo Gao; Peter A Fasching; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Diether Lambrechts; Els Van Nieuwenhuysen; Ignace Vergote; Sandrina Lambrechts; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Douglas A Levine; Lambertus A Kiemeney; Leon F A G Massuger; Jacek Gronwald; Jan Lubiński; Anna Jakubowska; Cezary Cybulski; Louise Brinton; Jolanta Lissowska; Nicolas Wentzensen; Honglin Song; Valerie Rhenius; Ian Campbell; Diana Eccles; Weiva Sieh; Alice S Whittemore; Valerie McGuire; Joseph H Rothstein; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Celeste L Pearce; Malcolm C Pike; Daniel O Stram; Anna H Wu; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Beata Spiewankiewicz; Marc T Goodman; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Florian Heitz; Andreas du Bois; Ira Schwaab; Philipp Harter; Jacobus Pisterer; Peter Hillemanns; Beth Y Karlan; Christine Walsh; Jenny Lester; Sandra Orsulic; Stacey J Winham; Madalene Earp; Melissa C Larson; Zachary C Fogarty; Estrid Høgdall; Allan Jensen; Susanne Kruger Kjaer; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Joellen M Schildkraut; Edwin S Iversen; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Irene Orlow; Tanja Pejovic; Yukie Bean; Claus Høgdall; Lene Lundvall; Ian McNeish; James Paul; Karen Carty; Nadeem Siddiqui; Rosalind Glasspool; Thomas Sellers; Catherine Kennedy; Yoke-Eng Chiew; Andrew Berchuck; Stuart MacGregor; Paul D P Pharoah; Ellen L Goode; Anna deFazio; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

View more
  2 in total

1.  Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer: influence on disease control.

Authors:  Heling Zhang; Ye Zhang
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  RTN2, a new member of circadian clock genes identified by database mining and bioinformatics prediction, is highly expressed in ovarian cancer.

Authors:  Xiaojiao Zheng; Xiuyi Lv; Jinghan Chai; Yi Huang; Linyan Zhu; Xianning Zhang
Journal:  Mol Med Rep       Date:  2022-09-30       Impact factor: 3.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.